Cargando…
Musings on genome medicine: Hepatitis C
Hepatitis C is a viral disease transmitted principally by blood, which affects millions of people worldwide. A significant proportion of those affected develop severe liver disease as a result. Only a fraction of patients are responsive to interferon treatment, highlighting the need for further rese...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2829929/ https://www.ncbi.nlm.nih.gov/pubmed/20193049 http://dx.doi.org/10.1186/gm125 |
_version_ | 1782178130793857024 |
---|---|
author | Nathan, David G Orkin, Stuart H |
author_facet | Nathan, David G Orkin, Stuart H |
author_sort | Nathan, David G |
collection | PubMed |
description | Hepatitis C is a viral disease transmitted principally by blood, which affects millions of people worldwide. A significant proportion of those affected develop severe liver disease as a result. Only a fraction of patients are responsive to interferon treatment, highlighting the need for further research into genetic factors involved in response to therapy in order to optimize treatment. The only current approach for end-stage disease is liver transplant, which ironically does not cure the condition, and thus poses a clinical dilemma in the face of liver-donor shortage. |
format | Text |
id | pubmed-2829929 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-28299292011-01-27 Musings on genome medicine: Hepatitis C Nathan, David G Orkin, Stuart H Genome Med Musings Hepatitis C is a viral disease transmitted principally by blood, which affects millions of people worldwide. A significant proportion of those affected develop severe liver disease as a result. Only a fraction of patients are responsive to interferon treatment, highlighting the need for further research into genetic factors involved in response to therapy in order to optimize treatment. The only current approach for end-stage disease is liver transplant, which ironically does not cure the condition, and thus poses a clinical dilemma in the face of liver-donor shortage. BioMed Central 2010-01-27 /pmc/articles/PMC2829929/ /pubmed/20193049 http://dx.doi.org/10.1186/gm125 Text en Copyright ©2010 BioMed Central Ltd |
spellingShingle | Musings Nathan, David G Orkin, Stuart H Musings on genome medicine: Hepatitis C |
title | Musings on genome medicine: Hepatitis C |
title_full | Musings on genome medicine: Hepatitis C |
title_fullStr | Musings on genome medicine: Hepatitis C |
title_full_unstemmed | Musings on genome medicine: Hepatitis C |
title_short | Musings on genome medicine: Hepatitis C |
title_sort | musings on genome medicine: hepatitis c |
topic | Musings |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2829929/ https://www.ncbi.nlm.nih.gov/pubmed/20193049 http://dx.doi.org/10.1186/gm125 |
work_keys_str_mv | AT nathandavidg musingsongenomemedicinehepatitisc AT orkinstuarth musingsongenomemedicinehepatitisc |